All In Biotech

Drug Trial Radar · NCT02603809

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2).

Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,659 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,659

Actual

Start

Dec 14, 2015

Primary completion

Feb 28, 2017

Study completion Apr 7, 2017

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Nov 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.

Conditions

  • Essential Hypertension

Interventions

  • Aprocitentan 5 mgDrug

    One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

  • Aprocitentan 10 mgDrug

    Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.

  • Aprocitentan 25 mgDrug

    One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

  • Aprocitentan 50 mgDrug

    One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.

  • Lisinopril 20 mgDrug

    One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan

  • PlaceboDrug

    One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at TroughTime frame: Baseline (Day 1) and end of double-blind treatment (Day 56)

Locations

90 sites in 4 countries. Site status is shown where the registry gives one.

  • Appalachian Cardiovascular Associates

    Fort Payne, Alabama

  • Radiant Research Inc

    Chandler, Arizona

  • Warner Family Practice / Radiant Research Inc

    Chandler, Arizona

  • Phoenix Medical Research Institute LLC

    Peoria, Arizona

  • Advanced Arizona Clinical Research

    Tucson, Arizona

  • Noble Clinical Research LLC

    Tucson, Arizona

  • Desert Sun Clinical Research LLc

    Tucson, Arizona

  • Advanced Research Center Inc

    Anaheim, California

  • Med Center

    Carmichael, California

  • John Muir Physician Network Clinical Research Center

    Concord, California

  • Clinical Trials Research

    Lincoln, California

  • Long Beach Center for Clinical Research

    Long Beach, California

  • Entertainment Medical Group Inc

    Los Angeles, California

  • Artemis institute for Clinical Research

    San Diego, California

  • Memorial Research Medical Clinic / Orange County Research Center

    Tustin, California

  • Empire Clinical Research

    Upland, California

  • Clinical Research Consulting LLC

    Milford, Connecticut

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Alfieri Cardiology

    Wilmington, Delaware

  • ACRC - Cardiology

    Atlantis, Florida

  • Innovative Research of West Florida INC

    Clearwater, Florida

  • Avail Clinical Research LLC

    DeLand, Florida

  • Alan Graff, MD, PA

    Fort Lauderdale, Florida

  • Gulfcoast Clinical Research Center

    Fort Myers, Florida

  • AGA Clinical Trials

    Hialeah, Florida

  • Canvas Clinical Research, LLC

    Lake Worth, Florida

  • LCC Medical Research Institute

    Miami, Florida

  • Allied Biomedical Research Institute, INC

    Miami, Florida

  • Southeast Regional Research Group

    Savannah, Georgia

  • Community Clin Res CTR

    Anderson, Indiana

  • Midwest Institute for Clinical Research

    Indianapolis, Indiana

  • Heartland Research Associated LLC

    Newton, Kansas

  • Heartland Research Associates LLC

    Wichita, Kansas

  • Heartland Research Associates LLC

    Wichita, Kansas

  • Avant Research Associates, LLC

    Crowley, Louisiana

  • Best Clinical Trials LLC

    New Orleans, Louisiana

  • New Orleans Center for Clinical Research - Nola

    New Orleans, Louisiana

  • Clinsite LLC

    Ann Arbor, Michigan

  • Primecare Research Associates, LLC

    Florissant, Missouri

  • Clinical Research Advantage, Inc. / Diagnostic Center Of Medicine - Durango

    Las Vegas, Nevada

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.